DUKE TXID SYMPOSIUM: NOVEL IMMUNOTHERAPIES IN TRANSPLANT RECIPIENTS AND PATIENTS WITH HEMATOLOGIC MALIGNANCIES UNDERSTANDING RISK AND STRATEGIES FOR INFECTION PREVENTION

November 11, 2022
  • Annual Transplant Infectious Diseases Symposium. An educational event featuring 6 medical and research experts in the fields of Infectious Diseases, Transplant Surgery, Immunology, and Cellular Therapy 6 - 30 minute intensive lecture sessions with Q&A sessions TITLE: Novel Immunotherapies in Transplant Recipients & Patients with Hematologic Malignancies: Understanding Risk & Strategies for Infection Prevention Topics and Speakers: Session 1: Proteosome Inhibitors (Bortezomib, Carfilzomib) for Multiple Myeloma:  Mechanism of action, outcomes including ‘duration of immunologic consequences” Speaker: John Wingard, MD, Price Eminent Scholar and Professor of Medicine, University of Florida Session2: Costimulation Blockade (Belatacept) + Proteosome Inhibition (Carfilzomib) for managing donor specific antibodies pre- and post-transplant Speaker:  Stuart J. Knechtle, MD , Duke University Session 3: Combining Immunologics:  prolonging survival or doubling trouble? Speaker:  Jennifer H. Saullo, MD, PharmD, Duke University Session 4: Chimeric antigen receptor (CAR) T-cell therapy for Cancer:  Infectious Risk Including Long-term Sequela Speaker:   Jon Huggins, MD. MSCE, Duke University Session 5: Virus Specific T-cell Therapies after Transplantation:  Donor specific or Off-the-Shelf: efficacy, availability Special Guest Speaker: Patrick Hanley, PhD, Chief Director, Cellular Therapy Program Associate Professor of Pediatrics, Children's National Hospital Session 6: Back to Basics:  Deciphering immunologic impact and infectious risk in the laboratory; Measuring pathogen specific B memory and plasma cells to assess vaccine induced immunity and infection risk Speaker:  Garnett H. Kelsoe. DSc,  Duke University

Target Audience

  • Fellows
  • Medical Students
  • Nurses
  • Nurse Practitioners
  • Physicians
  • Physician Assistants
  • Residents

Learning Objectives

  • Share knowledge with attendees about Proteosome inhibitors, including immunologic consequences.
  • Provide insides on Costimulation Blockade and Protesome inhibition for managing donor specific antibodies pre and post transplant.
  • Share information on combining immunologic agents and discerning if they prolong survival or create complications.
  • Discuss Chimeric antigen receptor T-cell therapy for Cancer including the infectious risk and long-term sequela.
  • Share insights on Virus Specific T-Cell Therapies after Transplantation, donor specific therapies vs. off-the shelf therapies, and their efficacy and availability.
  • Learning how to decipher immunologic impact and infectious risk in the laboratory along with measuring pathogen specific B memory and plasma cells to assess vaccine induced immunity and infection risk.
Course summary
Available credit: 
  • 6.00 AMA PRA Category 1 Credit(s)™
  • 6.00 ANCC
  • 6.00 Attendance
  • 6.00 IACET CEU
  • 6.00 JA Credit - AH
    • 6.00 Approved for AMA PRA Category 1 Credit(s)™
Registration Opens: 
11/11/2022
Registration Expires: 
11/11/2023
Activity Starts: 
11/11/2022 - 9:00am EST
Activity Ends: 
11/11/2022 - 4:30pm EST
Add to calendar: 
Rating: 
0
Durham, NC 27705
United States
  • Barbara Alexander, MD, MHS, Professor of Medicine & Pathology, Director, Transplant Infectious Diseases

          Committee member, Medical director, Moderator, Planner, Speaker

  • Jonathan Huggins, M.D., Assistant Professor of Medicine, Infectious Diseases

           Speaker

  • Lori College
  • Garnett H. Kelsoe, DSc, James B Duke Distinguished Professor of Immunology

           Speaker

  • Jennifer Saullo, MD, Assistant Professor of Medicine, Infectious Diseases

           Speaker

  • Maria Fryar
  • John Wingard, M.D. Price Eminent Scholar and Professor of Medicine, University of Florida

           Faculty Role: Committee member, Speaker

  • Amber Gay
  • Stuart Knechtle, M.D., William R. Keenan, Jr. Professor of Surgery, Executive Director Duke Transplant Center

         Faculty Role:  Committee member, Speaker

  • Monique McKinney
  • Patrick Hanley, Ph.D, Associate Professor Pediatrics, Children's National Hospital, Chief and Director of Cellular Therapy Program

          Faculty Role: Speaker

  • AMA PRA Category 1 Credit(s)
  • ANNC
  • JA Credit 
  • IACET CEU

Available Credit

  • 6.00 AMA PRA Category 1 Credit(s)™
  • 6.00 ANCC
  • 6.00 Attendance
  • 6.00 IACET CEU
  • 6.00 JA Credit - AH
    • 6.00 Approved for AMA PRA Category 1 Credit(s)™
Please login or register to take this course.